PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

IP strategy for AI-assisted drug discovery

  • Technology: AI drug discovery, Biotechnology, Pharmaceuticals
  • 29th April 2025
AI has been hailed as a potentially revolutionary tool for accelerating and enhancing the difficult and expensive process of drug discovery. Medicine perhaps represents the field in which AI has the most to offer humanity. However, the nascent field of AI-assisted drug design also highlights the need for IP strategy to be as forward-looking and innovative as the science it seeks to protect.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

Originally posted on IPKat. 

Firstly, strong IP protection for the clinical drug candidate will be of paramount importance, regardless of how the drug was discovered. For AI drug discovery platform companies there may also be highly valuable IP associated with the platform technology itself. An important question for such companies is when, and even if, to file patents for this IP. Finally, the life-blood of any company seeking to innovate in the pharmaceutical field is high quality data, and AI companies will be no exception. A successful IP strategy will have to balance each of these priorities. 

Fractional IP counsel

Protecting core product IP is paramount

Taking a drug product through clinical trials to launch takes many years and hundreds of millions of dollars of investment. As such, strong core IP covering the marketed drug product is generally regarded as essential, and the same will apply to AI-derived drugs. Patent protection for a new molecule entering clinical trials is how innovator pharmaceutical companies seek to ensure a return on investment for the millions of dollars required to take the drug through to market. For AI companies focused on drug discovery and design, a primary focus of the patent strategy should therefore be on ensuring strong core patent protection for the clinical candidate. As such, the patentability of a drug candidate must be a key component in drug design. Furthermore, the strength of the IP protecting a drug product will only be as strong as the science behind it. If your drug candidate is a mere obvious modification of a known product you will face an uphill battle convincing the patent office that you have a patentable invention, regardless of whether it was derived using an AI tool or through human endeavour. 

AI-drug discovery companies will also have to take care not to file too early for a drug candidate. The filing of a patent application starts the clock ticking on patent expiry and loss of exclusivity for a drug product. Additionally, the case law on sufficiency of disclosure with respect to in silico data and therapeutic effect is still developing. It is possible that the expected tsunami of chemical structure predictions from AI may even lead to an increase in the enablement requirement for a new chemical entity. Furthermore, the original molecule identified by an AI algorithm is likely to require further optimisation before it reaches the clinic, for example to take account of toxicity, manufacturability and in vivo efficacy. The final clinical candidate may therefore be different to that originally identified by the AI algorithm in silico. If the patent application was filed too early it may not therefore cover the eventual clinical lead and worse, may become citable prior art against a subsequent filing. As patent law currently stands, pursuing a patent based solely on AI-modelling data would be a brave decision indeed. 

A quick look at the patent filings of AI-assisted drug companies reveals that some may still be on a learning curve as far as developing and protecting core IP is concerned. Recursion Therapeutics is a Salt Lake City-based company focused on AI assisted phenotypic screening. On its website, Recursion promises to “leverage technology to reshape the typical drug discovery funnel by broadening the number of potential therapeutic starting points beyond hypothesized and human-biased targets“. However, whilst Recursion has multiple AI-optimised small molecule compounds in the clinic, a number of these compounds (REC-2282 and REC-4881) were known and patented by other parties, requiring Recursion to take a licence. Recursion also appears to be struggling in the prosecution of its own patent applications for its drug compounds. In one instance, the ISA has found the compounds defined by the pending claims as lacking in novelty, obvious as one of several straightforward possibilities, and/or not supported by any experimental data (WO 2024/039689). These examples are a good illustration of the principle that AI-assistance does not guarantee AI-invention (or patentability).

 Protecting the platform: To patent or trade secret? 

For companies seeking to build a platform for AI drug discovery, IP protection for the technology itself will also be of key importance. A critical question for such companies is whether the core technology should (and can) be protected by patents or whether trade secrets are more appropriate. Companies in the drug discovery field have to balance the benefits of patent protection for their platform technologies with the risks of disclosing the details of their technology to competitors. 

A primary reason for filing patents protecting the drug discovery platform may merely be to attract and reassure investors that the company has a concrete technological offering, and that this is protected by a strong metaphorical business “moat”. Additionally, having IP on file makes discussions with potential collaborators and partners safer and easier to conduct. 

However, there are also important potential downsides to patenting AI platform technology. The first of these is the fast moving nature of the field. A new algorithmic approach may become irrelevant in the three or four years it takes for a patent to grant, or even in the few months it takes to draft and file the patent application. Another downside to a solely patent-orientated approach to protecting platform IP is the time and resources associated with drafting and prosecuting a patent application. The complicated nature of AI technology means that any patent draft is likely to need a heavy degree of input from the inventors. Time taken assisting with patent drafts may thus consume valuable researcher time at the expense of further innovation. Finally, even if a patent is efficiently drafted and prosecuted, and is still relevant to a company’s technology when granted, the resulting patent may still be challenging to enforce. It can be difficult to know if a competitor is using your patented algorithmic approach behind their API. 

Given all the potential pitfalls of a patent-orientated approach, AI-drug discovery companies may therefore be tempted to protect their technology as trade secrets. A trade secret approach has the advantage that the details of the technology never have to be disclosed. However, a trade secret approach also has its disadvantages. The competitive nature of the AI-assisted drug discovery field may mean that if a company’s approach is particularly successful, it is highly likely to be reverse engineered by competitors. In such cases, trade secrets provide no protection. The success of OpenAI’s LLMs (i.e. ChatGPT) is a canonical example of how quickly fast followers can reproduce a technology once the general approach is known. We wait to see how and if OpenAI will choose to enforce its patents in the field. Furthermore, maintaining a successful trade secret policy can itself represent a significant challenge, especially in fluid and competitive labour markets such as AI. 

The decision whether to patent the AI platform technology must therefore be made on a case-by-case basis for each technological advance and type of company. Given the competitive and fast-paced nature of the field, a thoughtful and focused patent strategy would appear to offer the greatest advantage, at least for truly innovative companies with their sights on building a field defining AI-assisted drug discovery platform. 

Currently, there is a diversity of approach within the field. Some of the more established companies have little-or-no published patent applications relating to their platform, whilst other companies have taken a more aggressive patent strategy. Relay Therapeutics, an AI drug-design company focused on the optimisation of chemical structures by modelling molecular dynamics, has multiple products in the clinic but no platform patent applications filed in its name. Google DeepMind, by contrast, has many pending patent applications covering the different aspects and modules of AlphaFold, the core technology behind its AI-assisted drug discovery spin-out Isomorphic Labs. 

Final thoughts

It is tempting to think of AI-assisted drug discovery companies as just another category of platform company for drug development. However, there is a key distinction. Unlike other drug discovery platforms, effective AI-assisted drug discovery will be heavily reliant on vast quantities of high quality data. A machine learning model for accurately predicting the clinical efficacy, toxicity and manufacturability of a new drug will need a solid foundation of training data. At the moment, such data are primarily in the hands of large pharmaceutical companies. The IP strategy, and the associated commercialisation model of AI-assisted drug discovery companies, will therefore need to take account of the need for access to this data. This potentially places a huge bargaining chip in the hands of big pharma looking to partner with AI-drug discovery companies. In negotiations with the pharma industry, the ability for an AI platform company to demonstrate a strong IP position supported by a meaningful and effective patent strategy protecting truly innovative technology will likely bear the most fruit. 

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic inventions.
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image
Gold ball-and-stick molecule with one turquoise atom on dark blue, Evolve pharmaceuticals image

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025, we review the most impactful decisions of the year relating to clinical-stage inventions. 
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T 0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

From oil to gemstones: Our shifting understanding of the value of data

  • 10th October 2025
The concept of data as oil has been around for a number of years, but does the analogy still hold? In the pharma and biotech industry, there is now a shift away from thinking of data as a bulk commodity of raw material, towards the pursuit of high quality data that can improve the performance…
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.
Sphere of gold hexagon plates with glowing turquoise seams on dark blue, Evolve abstract article image.

An “immunogenic composition” is not a vaccine (T 0070/23)

  • 8th August 2025
While G1/24 mandates consulting the description, T 0070/23 is a crucial reminder of its limits. The case shows how the Board of Appeal refused to let a description definition override the clear technical meaning of a product claim.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice